[Pathogenesis of myasthenia gravis].
Onodera
Hiroshi
H
Department of Neurology, National Nishitaga Hospital, Kagitori-honmachi, Taihaku-ku, Sendai-shi, Miyagi 982-8555, Japan.
D001323:Autoantibodies; D018925:Chemokines / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000502:physiology; D007694:Killer Cells, Natural / Q000276:immunology; D008206:Lymphatic Diseases / Q000150:complications / Q000628:therapy; D009157:Myasthenia Gravis / Q000209:etiology* / Q000628:therapy; D009928:Organ Specificity / Q000276:immunology; D011978:Receptors, Nicotinic / Q000276:immunology; D015398:Signal Transduction / Q000502:physiology; D013934:Thymectomy; D013950:Thymus Gland
D001323:Autoantibodies; D018925:Chemokines; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011978:Receptors, Nicotinic